Home
→
Browsing by Author

Browsing by Author "Bravo, Isabel"

Now showing items 1-5 of 5

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

Kawana-Tachikawa, A.; Llibre, Josep M.; Bravo, Isabel; Escrig, R.; Mothe, B.; Puig, Jordi; Puertas, M.C.; Martinez Picado, Francisco Javier; Blanco, Julià; Manzardo, C.; Miró, J.M.; Iwamoto, A.; Pozniak, A.L.; Gatell, J.M.; Clotet, Bonaventura; Brander, Christian (Public Library of Science, 2014)

Background The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. Methods Subjects recently infected with HIV-1 were randomized to receive anti-retroviral ...
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia

Llibre, Josep M.; Bravo, Isabel; Ornelas, Arelly; Santos, José R.; Puig, Jordi; Martín Iguacel, Raquel; Paredes, Roger; Clotet, Bonaventura (Plos One, 2015)

Background Switching subjects with persistently undetectable HIV-1 viremia under antiretroviral treatment (ART) to once-daily tenofovir/emtricitabine (or lamivudine) + nevirapine is a cost-effective and well-tolerated ...
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice

Santos, José R.; Llibre, Josep M.; Berrio-Galan, Daniel; Bravo, Isabel; Miranda, Cristina; Pérez-Alvarez, Susana; Pérez Alvarez, Núria; Paredes, Roger; Clotet, Bonaventura; Moltó, José (Oxford University Press, 2015)

Background: Data on the efficacy of simplifying therapy using darunavir/ritonavir and lopinavir/ritonavir monotherapy in clinical practice remain limited. Methods: A retrospective single-centre study including patients ...
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (International AIDS Society, 2014)

Abstract INTRODUCTION: Previous studies have described improvements on lipid parameters when switching from other antiretroviral drugs to tenofovir (TDF) and impairments in lipid profile when discontinuing TDF. [1-3] It ...
The Lipid-Lowering Effect of Tenofovir/ Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Santos, José R.; Saumoy, M.; Curran, Adrian; Bravo, Isabel; Llibre, Josep M.; Navarro, Jordi; Estany, Carla; Podzamczer Palter, Daniel; Ribera, Esteban; Negredo, Eugenia; Clotet, Bonaventura; Paredes, Roger (Oxford University Press, 2015)

Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipidneutral emtricitabine (FTC), has a lipid-lowering effect. Methods. We performed a randomized, crossover, ...

Now showing items 1-5 of 5

Search RIUVic

Advanced Search

Browse

All of DSpace

Browsing by Author "Bravo, Isabel"

Browsing by Author "Bravo, Isabel"

Search RIUVic

Browse

All of DSpace